Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jennifer L. Driver"'
Autor:
Yun Zhu, Elizabeth C. Martin, Jennifer L. Driver, Steven Elliott, Bridgette M. Collins-Burow, Christopher W. Taylor, Lyndsay V. Rhodes, Mona Jodari-Karimi, Erik K. Flemington, Matthew E. Burow, Claire Fewell, Barbara S. Beckman, James W. Antoon
Publikováno v:
Molecular Carcinogenesis. 53:38-48
microRNAs (miRNA) are regulators of cellular pathways and alterations of normal miRNA expression levels have been shown to increase tumorigenesis. miR-24 has been demonstrated as having both tumor suppressive and oncogenic properties depending on cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4dedbbf80ac440fd434216d78bf26861
https://doi.org/10.1002/mc.21946
https://doi.org/10.1002/mc.21946
Autor:
Jennifer L. Driver, Steven Elliott, Evelyn M. Slaughter, James W. Antoon, Martin D. White, Hafez S. Khalili, Barbara S. Beckman, Matthew E. Burow, Charles D. Smith
Publikováno v:
Cancer Biology & Therapy. 11:678-689
Resistance to chemotherapy remains a significant obstacle in the treatment of hormone- independent breast cancer. Recent evidence suggests that altered sphingolipid signaling through increased sphingosine kinase activity may be an important mediator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd2bdbba58a382f2b46b718c48aa254b
https://doi.org/10.4161/cbt.11.7.14903
https://doi.org/10.4161/cbt.11.7.14903
Publikováno v:
Experimental biology and medicine (Maywood, N.J.). 237(7)
Sphingosine kinase signaling has become of increasing interest as a cancer target in recent years. Two sphingosine kinase inhibitors, sphingosine kinase inhibitor (SKI)-II and ABC294640, are promising as potential breast cancer therapies. However, ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::562653eca6659d04c49f862e393f4072
https://pubmed.ncbi.nlm.nih.gov/22859737
https://pubmed.ncbi.nlm.nih.gov/22859737
Autor:
Lyndsay V. Rhodes, F. Nell Pounder, Bridgette M. Collins-Burow, Jennifer L. Driver, H. Chris Segar, Chandra R. Tate, Matthew E. Burow
Publikováno v:
Breast Cancer Research : BCR
Introduction Of the more than one million global cases of breast cancer diagnosed each year, approximately fifteen percent are characterized as triple-negative, lacking the estrogen, progesterone, and Her2/neu receptors. Lack of effective therapies,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50281546e357def180747c9093c1f286
https://doi.org/10.1186/bcr3192
https://doi.org/10.1186/bcr3192
Autor:
Bridgette M. Collins-Burow, Steven Elliott, Meng Li, Elizabeth C. Martin, Lyndsay V. Rhodes, Ashley M. Nitschke, Matthew E. Burow, Seung Yoon Nam, Jennifer L. Driver, H. Chris Segar, Kenneth P. Nephew
Publikováno v:
Oncology Reports.
The development of drug resistance represents a major complication in the effective treatment of breast cancer. Epigenetic therapy, through the use of histone deacetylase inhibitors (HDACi) or demethylation agents, is an emerging area of therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7233ea69ba7e439cdff153ea6e3eabcf
https://doi.org/10.3892/or.2011.1488
https://doi.org/10.3892/or.2011.1488
Autor:
Matthew E. Burow, Shilong Zheng, Steven Elliott, Lyndsay V. Rhodes, Thomas E. Wiese, Florastina Payton-Stewart, Quan Jiang, Bridgette M. Collins-Burow, Cheryl L. Klein Stevens, Guangdi Wang, Qiang Zhang, Stephen M. Boue, Jennifer L. Driver, Jayalakshmi Sridhar, John A. McLachlan, Deepak Bhatnagar
Publikováno v:
Journal of medicinal chemistry. 53(16)
Daidzein (1) is a natural estrogenic isoflavone. We report here that 1 can be transformed into anti-estrogenic ligands by simple alkyl substitutions of the 7-hydroxyl hydrogen. To test the effect of such structural modifications on the hormonal activ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68ea721d14d7c8b66f856c5b2fb5adbe
https://pubmed.ncbi.nlm.nih.gov/20669983
https://pubmed.ncbi.nlm.nih.gov/20669983
Autor:
Jennifer L. Driver, M.M. Gestaut, Barbara S. Beckman, Evelyn M. Slaughter, James W. Antoon, Hafez S. Khalili, Charles D. Smith, Martin D. White, Matthew E. Burow, Steven Elliott
Publikováno v:
Cancer Research. 70:2537-2537
Resistance to chemotherapy is a major cause of breast cancer treatment failure today. The sphingolipid metabolizing enzyme sphingosine kinase converts pro-apoptotic ceramide into pro-survival sphingosine-1-phosphate (S1P). Sphingosine kinase has been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e102b7b486f082a1f8cfb71912f0f41d
https://doi.org/10.1158/1538-7445.am10-2537
https://doi.org/10.1158/1538-7445.am10-2537
Autor:
Lee Gibbs, Lyndsay V. Rhodes, KiTani A. Parker-Johnson, Hafez S. Khalili, Matthew E. Burow, Janeque Jones, Joseph Gallien, Tamorah Hawthorne, Jennifer L. Driver, Shannon E. Muir
Publikováno v:
Cancer Research. 70:4606-4606
Patients diagnosed with triple negative breast cancer, which is the absence of the estrogen (ER), progesterone (PR), and Her2/neu receptor have a poor prognosis and there is a critical need to develop novel antineoplastic agents for this breast cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2a0fdf0c9e6a42d340de3433292bd9e
https://doi.org/10.1158/1538-7445.am10-4606
https://doi.org/10.1158/1538-7445.am10-4606